Maintenance Treatment
48 articles
The Relatively New Procedure of Irreversible Electroporation Has Given Me Time
When chemotherapy and radiation stopped working, Leslie Wineberg was glad to qualify for irreversible electroporation (IRE).
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
Determined to Win
After a metastatic pancreatic cancer diagnosis, Linda Chambless sought a second opinion, which led her to a clinical trial.
Have Hope
Andy Seynaeve has undergone many rounds of chemotherapy but he has had a great response. Best of all, he has hope.
Changing Course Midstream
Barbara Green wasn’t happy with her doctors, so she took the advice of her support group, was an advocate for herself, and changed doctors.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
Time and Hope
Rose farmer Michael Francis wanted more time with his family, so he joined a clinical trial to treat his stage III pancreatic cancer.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Far More Time than I Originally Expected
After a Whipple procedure, SBRT, and chemotherapy, Robert Glazier is staying informed about treatment options for pancreatic cancer.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Clinical Trials Offer Hope to Patients and Clinicians Seeking a Cure
Philip Zeblisky describes his treatment for stage IV pancreatic cancer. He looked for clinical trials to find the best treatment.